Test Code HITIG Heparin-PF4 IgG Antibody, Serum
Useful For
Detection of IgG antibodies directed against heparin/platelet factor 4 complexes that are implicated in the pathogenesis of immune-mediated type II heparin-induced thrombocytopenia, spontaneous heparin platelet-factor 4 IgG antibody, and thrombocytopenia and thrombosis occurring after SARS-CoV2 adenovirus vector vaccine
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Reporting Name
Heparin-PF4 IgG Ab (HIT), SSpecimen Type
Serum RedSpecimen Required
Patient Preparation: Fasting is preferred but not required
Collection Container/Tube: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Stability Information: Frozen (preferred) 2 years/Refrigerate 7 days
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Frozen (preferred) | ||
Refrigerated | 7 days |
Reference Values
HIT ELISA:
<0.400
HIT Interpretation:
Negative
Interpretation
Results are reported as:
1. Heparin-induced thrombocytopenia (HIT) enzyme-linked immunosorbent assay (ELISA) optical density (OD)
2. Heparin inhibition (%)
3. Interpretation.
Typical patterns of results and interpretations are depicted in the following table. Interpretive comments will also accompany test reports, when indicated.
Table. Results and Interpretation
|
HIT ELISA OD |
Heparin inhibition |
Interpretation |
Normal range |
<0.400 |
Not done |
Negative |
Positive |
≥0.400 |
≥50% |
Positive |
Equivocal |
≥0.400 |
<50% |
Equivocal |
A negative result of testing for human platelet factor 4 (H/PF4) antibodies has about a 90% negative predictive value for exclusion of clinical type II HIT (HIT-II).
As up to 10% of patients with clinical HIT may have a negative H/PF4 antibody ELISA result, a negative H/PF4 antibody ELISA result does not exclude the diagnosis of HIT when clinical suspicion remains high. A functional assay for HIT antibodies (eg, heparin-dependent platelet aggregation or serotonin release assay) may be helpful in these circumstances. Call 800-533-1710 for ordering information.
A positive result is indicative of the presence of H/PF4 complex antibodies. However, this test's specificity is as low as 20% to 50% for clinical diagnosis of HIT, depending on the patient population studied. For example, up to 50% of surgical patients and up to 20% of medical patients treated with heparin may develop H/PF4 antibodies as measured by ELISA, and only a small proportion (1%-5%) develop clinical HIT. Accordingly, this test does not confirm the diagnosis of HIT-II. The diagnosis must be made in conjunction with clinical findings, including evaluation for other potential causes of thrombocytopenia.
The presence of H/PF4 antibodies likely increases the risk of clinical HIT, with risk probably partly dependent on associated medical and surgical conditions, but currently there is little data about relative risk of HIT in various populations with positive tests for H/PF4 antibodies.
Clinical Reference
1. Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A. Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(6):1203-1212. doi:10.1111/jth.13692
2. Warkentin TE, Greinacher A, eds. Heparin Induced Thrombocytopenia. Marcel Dekker; 2000:400
3. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312. doi:10.1111/j.1538-7836.2008.03025.x
4. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol. 1998;101(4):653-655. doi:10.1046/j.1365-2141.1998.00750.x
Day(s) Performed
Monday through Sunday
Report Available
1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86022
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
HITIG | Heparin-PF4 IgG Ab (HIT), S | 73818-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
46915 | HIT ELISA | 73818-7 |
21468 | Heparin Inhibition | 73817-9 |
21469 | HIT Interpretation | 73819-5 |
21470 | HIT Comment | 73816-1 |
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.